Gilda Tachedjian

List of Publications by Year
in descending order

101	4,552	94433 37	114465 63
papers	citations	h-index	g-index

107	107	107	4877
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Summary of the Sixth International Workshop on Microbiome in HIV Pathogenesis, Prevention, and Treatment. AIDS Research and Human Retroviruses, 2022, 38, 173-180.	1.1	0
2	Lactic acid-containing products for bacterial vaginosis and their impact on the vaginal microbiota: A systematic review. PLoS ONE, 2021, 16, e0246953.	2.5	29
3	HERV-K Gag RNA and Protein Levels Are Elevated in Malignant Regions of the Prostate in Males with Prostate Cancer. Viruses, 2021, 13, 449.	3.3	21
4	Retroviruses of Bats: a Threat Waiting in the Wings?. MBio, 2021, 12, e0194121.	4.1	11
5	The Effect of Exogenous Sex Steroids on the Vaginal Microbiota: A Systematic Review. Frontiers in Cellular and Infection Microbiology, 2021, 11, 732423.	3.9	13
6	A Summary of the Fifth Annual Virology Education HIV Microbiome Workshop. AIDS Research and Human Retroviruses, 2020, 36, 886-895.	1.1	2
7	Editorial: Interplay of Infection and Microbiome. Frontiers in Cellular and Infection Microbiology, 2020, 10, 304.	3.9	0
8	Infectious KoRV-related retroviruses circulating in Australian bats. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9529-9536.	7.1	31
9	Short Communication: Effect of Seminal Plasma on Functions of Monocytes and Granulocytes. AIDS Research and Human Retroviruses, 2019, 35, 553-556.	1.1	3
10	Risk of Subsequent HIV Infection Following Sexually Transmissible Infections Among Men Who Have Sex With Men. Open Forum Infectious Diseases, 2019, 6, ofz376.	0.9	9
11	Combined oral contraceptive pill-exposure alone does not reduce the risk of bacterial vaginosis recurrence in a pilot randomised controlled trial. Scientific Reports, 2019, 9, 3555.	3.3	22
12	A 30â€¯kDa polyethylene glycol-enfuvirtide complex enhances the exposure of enfuvirtide in lymphatic viral reservoirs in rats. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 137, 218-226.	4.3	9
13	Oxazole-Benzenesulfonamide Derivatives Inhibit HIV-1 Reverse Transcriptase Interaction with Cellular eEF1A and Reduce Viral Replication. Journal of Virology, 2019, 93, .	3.4	8
14	O05.4â€…The effect of the combined oral contraceptive pill on the vaginal microbiota of women treated for bacterial vaginosis. , 2019, , .		0
15	Molecular dissection of an inhibitor targeting the HIV integrase dependent preintegration complex nuclear import. Cellular Microbiology, 2019, 21, e12953.	2.1	17
16	Host and Viral Proteins Modulating Ebola and Marburg Virus Egress. Viruses, 2019, 11, 25.	3.3	28
17	The Evolving Facets of Bacterial Vaginosis: Implications for HIV Transmission. AIDS Research and Human Retroviruses, 2019, 35, 219-228.	1.1	188
18	Distinct Immune Responses Elicited From Cervicovaginal Epithelial Cells by Lactic Acid and Short Chain Fatty Acids Associated With Optimal and Non-optimal Vaginal Microbiota. Frontiers in Cellular and Infection Microbiology, 2019, 9, 446.	3.9	76

#	Article	IF	Citations
19	Differential Evolution of Antiretroviral Restriction Factors in Pteropid Bats as Revealed by APOBEC3 Gene Complexity. Molecular Biology and Evolution, 2018, 35, 1626-1637.	8.9	59
20	Anti-HIV-1 Activity of Lactic Acid in Human Cervicovaginal Fluid. MSphere, 2018, 3, .	2.9	66
21	The implausible â€œin vivoâ€•role of hydrogen peroxide as an antimicrobial factor produced by vaginal microbiota. Microbiome, 2018, 6, 29.	11.1	81
22	Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. Mucosal Immunology, 2017, 10, 1480-1490.	6.0	158
23	The role of lactic acid production by probiotic Lactobacillus species in vaginal health. Research in Microbiology, 2017, 168, 782-792.	2.1	336
24	Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4 ⁺ T Cells following Latency Reversal. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	11
25	Critical Review. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 1-7.	2.1	16
26	Combination anti-HIV therapy via tandem release of prodrugs from macromolecular carriers. Polymer Chemistry, 2016, 7, 7477-7487.	3.9	20
27	Increasing prevalence of K65K and K66K in HIV-1 subtype B reverse transcriptase. Aids, 2016, 30, 2787-2793.	2.2	1
28	Contraction of the type I IFN locus and unusual constitutive expression ofIFN-Î±in bats. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2696-2701.	7.1	272
29	High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo. Virology, 2016, 492, 1-10.	2.4	10
30	Why Do We Need New Drug Classes for HIV Treatment and Prevention?. Current Topics in Medicinal Chemistry, 2016, 16, 1343-1349.	2.1	19
31	Bats and Rodents Shape Mammalian Retroviral Phylogeny. Scientific Reports, 2015, 5, 16561.	3.3	31
32	Editorial (Thematic Issue: Current and Emerging Drug Targets for Human Immunodeficiency Virus). Current Topics in Medicinal Chemistry, 2015, 16, 1072-1073.	2.1	0
33	Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. Frontiers in Physiology, 2015, 6, 164.	2.8	240
34	Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 6979-6984.	7.1	22
35	Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations. Nucleic Acids Research, 2015, 43, 3256-3271.	14.5	9
36	Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors. Current Topics in Medicinal Chemistry, 2015, 16, 1135-1153.	2.1	6

#	Article	IF	Citations
37	Lactic Acid, a Vaginal Microbiota Metabolite, Elicits an Anti-inflammatory Response from Vaginal and Cervical Epithelial Cells. AIDS Research and Human Retroviruses, 2014, 30, A238-A239.	1.1	7
38	Drug Resistant SIV Strains Carrying Higher-Fidelity K65R and Q151N Reverse Transcriptase Mutations Are Less Fit In Vivo. AIDS Research and Human Retroviruses, 2014, 30, A185-A185.	1.1	0
39	Vaginal Concentrations of Lactic Acid Potently Inactivate HIV-1 Compared to Short Chain Fatty Acids Present During Bacterial Vaginosis. AIDS Research and Human Retroviruses, 2014, 30, A228-A228.	1.1	5
40	Identification of diverse full-length endogenous betaretroviruses in megabats and microbats. Retrovirology, 2013, 10, 35.	2.0	45
41	No association between XMRV or related gammaretroviruses in Australian prostate cancer patients. Virology Journal, 2013, 10, 20.	3.4	9
42	Vaginal concentrations of lactic acid potently inactivate HIV. Journal of Antimicrobial Chemotherapy, 2013, 68, 2015-2025.	3.0	135
43	HIV-1 Infection of T Cells and Macrophages Are Differentially Modulated by Virion-Associated Hck: A Nef-Dependent Phenomenon. Viruses, 2013, 5, 2235-2252.	3.3	5
44	The NRTIs Lamivudine, Stavudine and Zidovudine Have Reduced HIV-1 Inhibitory Activity in Astrocytes. PLoS ONE, 2013, 8, e62196.	2.5	46
45	Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. PLoS ONE, 2013, 8, e69266.	2.5	19
46	Role of RNase H Activity in NRTI/NNRTI Drug Resistance. , 2013, , 281-303.		1
47	Discovery of Retroviral Homologs in Bats: Implications for the Origin of Mammalian Gammaretroviruses. Journal of Virology, 2012, 86, 4288-4293.	3.4	52
48	N348I in HIV-1 Reverse Transcriptase Counteracts the Synergy Between Zidovudine and Nevirapine. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 153-157.	2.1	7
49	Phosphatidylethanolamine Binding Is a Conserved Feature of Cyclotide-Membrane Interactions. Journal of Biological Chemistry, 2012, 287, 33629-33643.	3.4	115
50	Identification of diverse groups of endogenous gammaretroviruses in mega- and microbats. Journal of General Virology, 2012, 93, 2037-2045.	2.9	48
51	Identification of residues involved in NS2 homodimerization and elucidation of their impact on the HCV life cycle. Journal of Viral Hepatitis, 2012, 19, 189-198.	2.0	8
52	Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. Antiviral Research, 2011, 90, 195-199.	4.1	83
53	Decoding the Membrane Activity of the Cyclotide Kalata B1. Journal of Biological Chemistry, 2011, 286, 24231-24241.	3.4	155
54	SPL7013 Gel (VivaGelÂ®) Retains Potent HIV-1 and HSV-2 Inhibitory Activity following Vaginal Administration in Humans. PLoS ONE, 2011, 6, e24095.	2.5	139

#	Article	IF	Citations
55	N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. Aids, 2010, 24, 317-319.	2.2	22
56	N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations. Aids, 2010, 24, 659-667.	2.2	21
57	Structure Activity Relationship of Dendrimer Microbicides with Dual Action Antiviral Activity. PLoS ONE, 2010, 5, e12309.	2.5	147
58	Ubisol-AquaTM: Coenzyme Q10 Prevents Antiretroviral Toxic Neuropathy in an In Vitro Model. Current HIV Research, 2010, 8, 232-239.	0.5	5
59	Enhancement of Human Immunodeficiency Virus Type 1 Replication Is Not Intrinsic to All Polyanion-Based Microbicides. Antimicrobial Agents and Chemotherapy, 2009, 53, 3565-3568.	3.2	9
60	The Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutation I132M Confers Hypersensitivity to Nucleoside Analogs. Journal of Virology, 2009, 83, 3826-3833.	3.4	17
61	Maturation of the HIV reverse transcription complex: putting the jigsaw together. Reviews in Medical Virology, 2009, 19, 324-337.	8.3	45
62	Effect of Reverse Transcriptase Inhibitors and Mutations on the Low-Cost Cavidi Reverse Transcriptase Viral Load Assay. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 527-529.	2.1	5
63	Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Research, 2008, 134, 147-156.	2.2	135
64	Impact of Residues in the Nonnucleoside Reverse Transcriptase Inhibitor Binding Pocket on HIV-1 Reverse Transcriptase Heterodimer Stability. Current HIV Research, 2008, 6, 130-137.	0.5	20
65	Alteration of the Proline at Position 7 of the HIV-1 Spacer Peptide p1 Suppresses Viral Infectivity in a Strain Dependent Manner. Current HIV Research, 2007, 5, 69-78.	0.5	6
66	Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51ÂkDa subunit of HIV-1 RT. Biochemical Journal, 2007, 404, 151-157.	3.7	22
67	Targeting Human Immunodeficiency Virus Type 1 Assembly, Maturation and Budding. Drug Target Insights, 2007, 2, 117739280700200.	1.4	9
68	N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance. PLoS Medicine, 2007, 4, e335.	8.4	151
69	Targeting human immunodeficiency virus type 1 assembly, maturation and budding. Drug Target Insights, 2007, 2, 159-82.	1.4	5
70	Dimerization of Human Immunodeficiency Virus Type 1 Reverse Transcriptase as an Antiviral Target. Current Pharmaceutical Design, 2006, 12, 1879-1894.	1.9	35
71	Potent Nonnucleoside Reverse Transcriptase Inhibitors Target HIV-1 Gag-Pol. PLoS Pathogens, 2006, 2, e119.	4.7	95
72	Relationship between enzyme activity and dimeric structure of recombinant HIV-1 reverse transcriptase. Proteins: Structure, Function and Bioinformatics, 2005, 60, 5-13.	2.6	16

#	Article	IF	Citations
73	Evaluation of a Low Cost Reverse Transcriptase Assay for Plasma HIV-1 Viral Load Monitoring. Current HIV Research, 2005, 3, 183-190.	0.5	37
74	Antiretroviral Compounds: Mechanisms Underlying Failure of HAART to Eradicate HIV-1. Current Medicinal Chemistry, 2005, 12, 1705-1719.	2.4	44
75	Analysis of the Contribution of Reverse Transcriptase and Integrase Proteins to Retroviral RNA Dimer Conformation. Journal of Virology, 2005, 79, 6338-6348.	3.4	17
76	The Packaging and Maturation of the HIV-1 Pol Proteins. Current HIV Research, 2005, 3, 73-85.	0.5	55
77	Mutations That Abrogate Human Immunodeficiency Virus Type 1 Reverse Transcriptase Dimerization Affect Maturation of the Reverse Transcriptase Heterodimer. Journal of Virology, 2005, 79, 10247-10257.	3.4	54
78	Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation. FEBS Letters, 2005, 579, 379-384.	2.8	46
79	Virological significance, prevalence and genetic basis of hypersusceptibility to nonnucleoside reverse transcriptase inhibitors. Sexual Health, 2004, 1, 81.	0.9	4
80	Role of Residues in the Tryptophan Repeat Motif for HIV-1 Reverse Transcriptase Dimerization. Journal of Molecular Biology, 2003, 326, 381-396.	4.2	64
81	The effect of NNRTIs on HIV reverse transcriptase dimerization. Current Opinion in Investigational Drugs, 2003, 4, 966-73.	2.3	17
82	Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. FEBS Journal, 2002, 269, 5103-5111.	0.2	45
83	Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 7188-7193.	7.1	107
84	Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 6334-6339.	7.1	56
85	Short Communication: Impaired Fitness of Foscarnet-Resistant Strains of Human Immunodeficiency Virus Type 1. AIDS Research and Human Retroviruses, 1998, 14, 1059-1064.	1.1	14
86	Coresistance to Zidovudine and Foscarnet Is Associated with Multiple Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrobial Agents and Chemotherapy, 1998, 42, 3038-3043.	3.2	13
87	Antiviral Activity of DG-35-VIII, a Potent Inhibitor of the Protease of Human Immunodeficiency Virus. Antiviral Chemistry and Chemotherapy, 1997, 8, 99-106.	0.6	6
88	Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. Journal of Virology, 1996, 70, 7171-7181.	3.4	70
89	An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine. Journal of Virology, 1996, 70, 8010-8018.	3.4	108
90	Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. Journal of Medical Virology, 1995, 46, 238-243.	5.0	18

#	Article	IF	Citations
91	Characterisation of Foscarnet-Resistant Strains of Human Immunodeficiency Virus Type 1. Virology, 1995, 212, 58-68.	2.4	44
92	Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patient. Journal of Medical Virology, 1994, 42, 207-211.	5.0	12
93	Cellular Topoisomerase I Activity Associated with HIV-1. AIDS Research and Human Retroviruses, 1993, 9, 1245-1250.	1.1	21
94	Clinical Effects and In Vitro Studies of Trifluorothymidine Combined with Interferon-Â for Treatment of Drug-Resistant and -Sensitive Herpes Simplex Virus Infections. Journal of Infectious Diseases, 1992, 166, 108-112.	4.0	60
95	Synergistic Inhibition of Human Immunodeficiency Virus Type 1 in vitro by Interferon Alpha and Coumermycin A1. Antiviral Chemistry and Chemotherapy, 1992, 3, 183-188.	0.6	5
96	Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B Virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. Journal of Medical Virology, 1990, 31, 90-97.	5.0	61
97	Investigation of Topoisomerase Inhibitors for Activity against Human Immunodeficiency Virus: Inhibition by Coumermycin A1. Antiviral Chemistry and Chemotherapy, 1990, 1, 131-138.	0.6	15
98	Altered Sensitivity to Antiviral Drugs of Herpes Simplex Virus Isolates from a Patient with the Acquired Immunodeficiency Syndrome. Journal of Infectious Diseases, 1990, 162, 731-734.	4.0	69
99	In Vitro Effectiveness of a Combination of Zidovudine and Ansamycin Against Human Immunodeficiency Virus. Journal of Infectious Diseases, 1988, 158, 895-895.	4.0	0
100	Diethanolamine fusidate has no inâ€vitro activity against the human immunodeficiency virus. Medical Journal of Australia, 1988, 149, 224-225.	1.7	2
101	The Impact of Over-The-Counter Lactic Acid Containing Vaginal Gels on the Integrity and Inflammatory State of the Vaginal Epithelium in vitro. Frontiers in Reproductive Health, 0, 4, .	1.9	2